House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Neurology

Motor neurone disease: assessment and management

NICE · 2019 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

This NICE guideline (NG42) covers recognising, diagnosing and managing motor neurone disease (MND). It addresses early presentations and referral, how the diagnosis is shared, cognitive assessment, prognostic factors and specialist multidisciplinary care. It also covers drug and non-drug symptom control, nutrition and gastrostomy, communication aids, respiratory monitoring with test thresholds, non-invasive ventilation (NIV), cough augmentation and end-of-life planning. Recommendations are dated 2010 or 2016, with one amended in 2024.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Recognition, referral and diagnosis

  • MND causes progressive weakness, and its first signs may be isolated, unexplained symptoms. These include loss of dexterity or falls, and bulbar speech or swallowing problems or tongue fasciculations. Other early signs are muscle wasting, twitching or cramps, and reduced respiratory function such as daytime sleepiness, morning headache or breathlessness lying down. Cognitive features, including frontotemporal dementia, may also come first. [1]
  • Refer suspected MND without delay and name the possible diagnosis in the referral letter. Contact the consultant neurologist directly if urgent review seems needed. Inform the GP without delay. Support the person and family through any diagnostic uncertainty or delay. [1]
  • A consultant neurologist experienced in MND should give information on diagnosis, prognosis and management, unless an urgent situation requires otherwise. Ask how much information the person wants, and give it orally and in writing. Provide a single multidisciplinary team (MDT) contact. Offer a face-to-face MDT follow-up within 4 weeks of diagnosis. [1]
  • Explore cognitive and behavioural change at diagnosis and whenever concerns arise. If needed, refer for formal assessment in line with NICE dementia guidance. People with MND and frontotemporal dementia may lack capacity; follow the Mental Capacity Act 2005. [1]

Organisation of care and prognosis

  • Coordinate care through a specialist MND MDT clinic, which may be community or hospital based. Assess usually every 2 to 3 months, adjusting frequency to need. Coordinate care for people who cannot attend. [1]
  • Have arrangements to bring MDT review forward after a significant symptom change. Because MND can worsen quickly, prioritise continuity and avoid untimely case closure. [1]
  • When planning care, take account of factors present at diagnosis that are linked to shorter survival. These are bulbar presentation, weight loss, poor respiratory function, older age, a lower ALSFRS/ALSFRS-R score and a shorter interval from symptom onset to diagnosis. [1]
  • Consider specialist palliative care referral for current or anticipated significant or complex needs. Examples are psychological or social distress, troublesome or rapidly progressing symptoms, and complex future care planning. [1]

Symptom management and disease-modifying treatment

  • For cramps, consider quinine first-line. If it is ineffective, not tolerated or contraindicated, consider baclofen. If baclofen is also unsuitable, consider tizanidine, dantrolene or gabapentin. Quinine, baclofen, tizanidine and dantrolene were off-label in February 2016. MHRA safety advice on gabapentin is referenced. [1]
  • For stiffness, spasticity or increased tone, consider baclofen, tizanidine, dantrolene or gabapentin. If these fail or are unsuitable, consider referral to a specialist service for severe spasticity. Dantrolene was off-label in February 2016. [1]
  • For drooling, advise on swallowing, diet, posture, positioning, oral care and suctioning. Consider an antimuscarinic trial first-line. With cognitive impairment, consider glycopyrronium bromide first-line because it has fewer CNS effects. Both were off-label uses in February 2016. Consider specialist referral for botulinum toxin A as first- or second-line treatment. [1]
  • Riluzole is a NICE technology-appraisal option for the amyotrophic lateral sclerosis form of MND (TA20). [1]

Nutrition, gastrostomy and communication

  • Arrange a clinical swallowing assessment if problems are suspected. Discuss gastrostomy early and at regular intervals. Explain the benefits of early placement and the risks of late placement, and accept that some people will decline. Once a person is referred, gastrostomy should go ahead without unnecessary delay. [1]
  • A speech and language therapist should assess communication without delay, covering face-to-face and remote communication. Provide suitable augmentative and alternative communication (AAC) equipment without delay. Involve a specialised NHS AAC hub if complex high-technology equipment such as eye gaze access is needed now or is likely to be needed. [1]

Respiratory assessment, ventilation and cough

  • Monitor respiratory function and symptoms. If impairment worsens, treat reversible causes such as infection or secretion problems before other treatments. Consider urgent NIV for people not already using it. [1]
  • At or soon after diagnosis, record a single SpO2 at rest on room air. Refer to a respiratory ventilation service if pulse oximetry cannot be done locally. Then perform one or both of FVC/VC and SNIP and/or MIP. Oximeters can misread borderline values and may overestimate saturation in people with dark skin. [1]
  • Some people have severe bulbar impairment, or severe cognitive problems that may be related to respiratory impairment. For them, ensure SpO2 is measured at rest on room air, but omit FVC, VC, SNIP and MIP if the interfaces are unsuitable. Repeat respiratory tests usually every 2 to 3 months, more or less often as needed. [1]
  • Perform arterial or capillary blood gas analysis if resting room-air SpO2 is 92% or less with known lung disease, or 94% or less without it. Refer to a ventilation service if this testing is unavailable locally. If saturation is above these thresholds but there are sleep-related symptoms, consider referral for overnight oximetry and/or a limited sleep study. [1]
  • If PaCO2 exceeds 6 kPa, refer urgently to a respiratory ventilation service (seen within 1 week) and explain why. If PaCO2 is 6 kPa or less but symptoms or signs are present, especially orthopnoea, refer for overnight oximetry and/or a limited sleep study. [1]
  • Discuss impairment, treatment options and possible referral, guided by the person's wishes, in any of these situations. First, FVC/VC below 50% of predicted value, or SNIP/MIP below 40 cmH2O. Second, symptoms or signs (particularly orthopnoea) with FVC/VC below 80% of predicted value, or SNIP/MIP below 65 cmH2O (men) or 55 cmH2O (women). Third, SNIP/MIP falling by more than 10 cmH2O per 3 months. [1]
  • Offer an NIV trial when clinical features and test results suggest likely benefit. For severe bulbar impairment, or severe cognitive problems that may be related to respiratory impairment, consider a trial only if sleep-related symptoms may improve or hypoventilation may be corrected. Acclimatise while awake during the day, usually begin regular use at night, and increase hours gradually. [1]
  • Offer cough augmentation when cough is ineffective. Consider unassisted breath stacking and/or manual assisted cough first. Consider assisted breath stacking (for example, a lung volume recruitment bag) for bulbar dysfunction or when unassisted stacking fails. Consider a mechanical cough assist device if assisted stacking fails and/or during respiratory infection. [1]
  • Consider opioids for breathlessness, and benzodiazepines for breathlessness made worse by anxiety, taking route and cost into account. For NIV users, consider prescribing these for as-needed use at home. Each use was off-label in February 2016. [1]

End-of-life planning and care

  • Offer end-of-life discussions at trigger points such as diagnosis, a significant respiratory change, or when gastrostomy or NIV is needed. Take account of communication, cognition and capacity. Discuss advance care planning earlier if these are expected to decline. Offer people the opportunity to talk about and review any existing ADRT, DNACPR orders and Lasting Power of Attorney when interventions such as gastrostomy or NIV are planned. [1]
  • Near the end of life, ensure prompt access to suitable communication methods, specialist palliative care and anticipatory medicines. These include opioids and benzodiazepines for breathlessness, and antimuscarinics for saliva and secretions. Explain that NIV can be stopped at any time. If someone on continuous NIV wants to stop, seek advice from experienced professionals. [1]

Limitations and use

  • This summary is based only on the clinical recommendations chapter. Research recommendations, rationale and impact, update history and committee information were not reviewed.
  • Flowcharts and visual algorithms were available only as alternative text.
  • The source shows recommendation dates (2010, 2016, one amended 2024) but no overall publication or update date. The requested 2019 year label could not be confirmed from the text.
  • Several recommendations defer to other NICE guidance not reviewed here: riluzole TA20, Xeomin TA605, dementia, nutrition support, supporting adult carers, care of dying adults, and patient experience.
  • Off-label status statements reflect February 2016.
  • The source refers to specific legal and administrative frameworks: the Mental Capacity Act 2005, ADRT, DNACPR orders, Lasting Power of Attorney and DVLA notification. Their applicability elsewhere is not addressed.
  • This summary omits detailed recommendations on social care, psychological support, equipment and adaptations, exercise and orthoses, and thick saliva. It also omits NIV risk assessment and care planning, and gastrostomy or NIV decisions in frontotemporal dementia.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Motor neurone disease: assessment and management

    Guideline recommendation text consulted

Original guideline

Publication details

Issuing organisation
NICE
First published
24 February 2016
Publisher’s latest update
23 July 2019
Resource type
Clinical guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Recognition, referral and diagnosis
  • Organisation of care and prognosis
  • Symptom management and disease-modifying treatment
  • Nutrition, gastrostomy and communication
  • Respiratory assessment, ventilation and cough
  • End-of-life planning and care
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House